1-hydroxymethylmidazolam has been researched along with salmeterol xinafoate in 1 studies
| Studies (1-hydroxymethylmidazolam) | Trials (1-hydroxymethylmidazolam) | Recent Studies (post-2010) (1-hydroxymethylmidazolam) | Studies (salmeterol xinafoate) | Trials (salmeterol xinafoate) | Recent Studies (post-2010) (salmeterol xinafoate) |
|---|---|---|---|---|---|
| 163 | 46 | 49 | 1,872 | 684 | 398 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayliss, MK; Eddershaw, PJ; Herriott, D; Manchee, GR; Park, GR; Ranshaw, LE; Tarbit, MH | 1 |
1 other study(ies) available for 1-hydroxymethylmidazolam and salmeterol xinafoate
| Article | Year |
|---|---|
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Topics: Adrenergic beta-Agonists; Albuterol; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Humans; Isoenzymes; Ketoconazole; Microsomes, Liver; Midazolam; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Salmeterol Xinafoate; Sulfaphenazole; Theophylline | 1996 |